TriSalus Life Sciences (TLSIW) Non-Current Deffered Revenue (2020 - 2023)

TriSalus Life Sciences (TLSIW) has 4 years of Non-Current Deffered Revenue data on file, last reported at $8.8 million in Q2 2023.

• For the quarter ending Q2 2023, Non-Current Deffered Revenue changed 0.0% year-over-year to $8.8 million; the trailing twelve-month figure through Jun 2023 stood at $8.8 million (changed 0.0% YoY), and the FY2022 full-year result was $8.8 million, changed 0.0% from the prior year.
• Non-Current Deffered Revenue for Q2 2023 stood at $8.8 million, roughly flat from $8.8 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $8.8 million in Q4 2020 and bottomed at $8.8 million in Q4 2020.
• The 4-year median for Non-Current Deffered Revenue is $8.8 million (2020), against an average of $8.8 million.
• Peak annual rise in Non-Current Deffered Revenue reached 0.0% in 2021, while the deepest fall reached 0.0% in 2021.
• A 4-year view of Non-Current Deffered Revenue shows it stood at $8.8 million in 2020, then changed by 0.0% to $8.8 million in 2021, then changed by 0.0% to $8.8 million in 2022, then changed by 0.0% to $8.8 million in 2023.
• The last three Non-Current Deffered Revenue figures came in at $8.8 million (Q2 2023), $8.8 million (Q1 2023), and $8.8 million (Q4 2022), per Business Quant data.

Peer Comparison